Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 54 clinical trials
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Phase III, prospective, multi-center, randomized, open label, parallel group, study in patients with HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy with 1:1 allocation to: Arm A: Sacituzumab govitecan (days 1, 8 q3w for eight cycles); Arm B: treatment of physicians choice (TPC, defined as capecitabine or platinum-based chemotherapy …

  • 0 views
  • 26 Jan, 2021
  • 32 locations
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

To verify that combination therapy with trastuzumab + pertuzumab + eribulin brings similar PFS and better QOL compared to trastuzumab + pertuzumab + taxane in advanced/recurrent HER2-positive

HER2
mammogram
taxane
paclitaxel
her2/neu-positive breast cancer
  • 14 views
  • 21 Jan, 2021
  • 2 locations
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2

HER2
growth factor
epidermal growth factor receptor
estrogen
progesterone receptor
  • 0 views
  • 25 Jan, 2021
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

The trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks).

HER2
invasive breast cancer
estrogen
carcinoma
progesterone receptor
  • 0 views
  • 25 Jan, 2021
  • 1 location
Anastrozole Palbociclib Trastuzumab and Pertuzumab in Her-positive Her2-positive Metastatic Breast

This is a multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab is proposed as first-line therapy in metastatic hormone receptor-positive, HER2-positive breast

core needle biopsy
HER2
mammogram
ejection fraction
estradiol
  • 38 views
  • 24 Jan, 2021
  • 4 locations
Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

The purpose of this phase II is to study the efficacy and toxicity of carboplatin and paclitaxel with pertuzumab and trastuzumab in HER2 positive and carboplatin and paclitaxel with bevacizumab

HER2
inflammatory breast cancer
mammogram
carcinoma
breast carcinoma
  • 46 views
  • 25 Jan, 2021
  • 1 location
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients

This is an open label, single arm, multicenter, phase Ib study to evaluate the safety and clinical activity of the combination of ipatasertib, trastuzumab and pertuzumab in patients with

HER2
invasive breast cancer
platelet count
breast adenocarcinoma
immunological adjuvant
  • 0 views
  • 25 Jan, 2021
  • 6 locations
Pyrotinib Trastuzumab Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

This study aims to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, pertuzumab and nab-paclitaxel as neoadjuvant therapy in early stage or locally advanced HER2

HER2
estrogen
carcinoma
progesterone receptor
primary tumor
  • 0 views
  • 24 Jan, 2021
  • 1 location
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

The purpose of this study is to find out if radiation therapy followed by intrathecal trastuzumab and pertuzumab is safe and will result in improved survival in HER2 positive breast cancer which

  • 0 views
  • 28 Jan, 2021
  • 1 location
Testing a New Imaging Agent to Identify Cancer

The purpose of this study is to see whether 89Zr-ss-pertuzumab is safe in people with HER2+ cancer. The study will also test whether the PET/CT pictures taken using 89Zr-ss-pertuzumab are better

  • 0 views
  • 03 Mar, 2021
  • 2 locations